Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593116 | 0.82 | CNR1 (0.43) | GABRA2GABRB2CNR1CNR2 | |
| SCHEMBL13593119 | 0.79 | TSPO (0.43) | TP53MEN1ALDH1A1KMT2ARAB9A | |
| SCHEMBL13593111 | 0.78 | CNR1 (0.52) | MAPTALDH1A1SMN1; SMN2CNR1CNR2 | |
| SCHEMBL13593109 | 0.78 | CNR1 (0.50) | ALDH1A1RAB9ANPC1CNR1CNR2 | |
| SCHEMBL13593117 | 0.77 | CNR1 (0.41) | CNR1CNR2 | |
| SCHEMBL13593118 | 0.77 | CNR1 (0.46) | MAPTKDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL3552117 | 0.76 | CNR1 (0.43) | TP53HSD17B10KDM4EALDH1A1RAB9A | |
| SCHEMBL13593110 | 0.76 | EPAS1 (0.48) | TP53MAPTKDM4EMEN1HPGD | |
| SCHEMBL13593115 | 0.76 | ALDH1A1 (0.51) | HSD17B10ALDH1A1HPGDRAB9ANPC1 | |
| SCHEMBL13593113 | 0.75 | CNR1 (0.52) | KMT2ARAB9ANPC1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2006138657-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | CNR1, CNR2, GPR18 | TP53 4555/4885RXFP1 101/4885MAPT 4012/4885 |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TP53 4555/4885RXFP1 101/4885MAPT 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.